Evidence map›Paper›PMID 38073461›Full record

ArticleCancer medicine2023

Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival.

Olivia Davis, Derek Truong, Silas Day, Manu Pandey, Sami Ibrahimi, Mohamad Khawandanah, Jennifer Holter-Chakrabarty, Adam Asch, Taha Al-Juhaishi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Olivia DavisCollege of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Derek TruongDepartment of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Silas DayHematology/Oncology Clinical Trials Office, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Manu PandeyDepartment of Medicine, Section of Hematology and Medical Oncology, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Sami IbrahimiDepartment of Medicine, Section of Hematology and Medical Oncology, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Mohamad KhawandanahDepartment of Medicine, Section of Hematology and Medical Oncology, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Jennifer Holter-ChakrabartyDepartment of Medicine, Section of Hematology and Medical Oncology, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Adam AschDepartment of Medicine, Section of Hematology and Medical Oncology, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Taha Al-JuhaishiDepartment of Medicine, Section of Hematology and Medical Oncology, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0002-8359-0178
University of Oklahoma Health Sciences Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPeripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a rare, highly heterogeneous group of mature T-cell neoplasms that historically has been associated with poor outcomes. We sought to investigate the influence of primary disease site on PTCL-NOS outcomes using a large national cancer registry.

methodsBaseline clinical and demographic data including primary organ of involvement and Ann Arbor disease stage were extracted from the SEER database. Patients were grouped into nine organ system groups and compared to nodal disease acting as a control. Cox regression models were utilized for adjusted survival analyses.

resultsA total of 3095 patients were identified in the SEER database and included in the final analysis. The median age was 61 and a majority of patients were male (60%) and identified as non-Hispanic white (68%). A plurality of patients had stage IV disease (32%). Lymph nodes and spleen were the most common primary disease sites (67%), while central nervous system was the least common (1%). Patients with early-stage PTCL-NOS of the gastrointestinal/genitourinary systems had worse overall survival [HR = 1.97 (1.50-2.59); p < 0.001] and lymphoma-specific survival [HR = 1.74 (1.26-2.40); p < 0.001] which was statistically significant even after adjusting for other variables. Early-stage PTCL-NOS of the central nervous system also had worse overall survival [HR = 1.90 (1.11-3.27); p = 0.020] and lymphoma-specific survival [HR = 2.11 (1.17-3.80); p = 0.013]. Early-stage PTCL-NOS of the skin had better overall survival [HR = 0.54 (0.42-0.68); p < 0.001] and lymphoma-specific survival [HR = 0.388 (0.28-0.53); p < 0.001] which was statistically significant even after adjustments.

conclusionOur findings suggest an association between primary organ involved by PTCL-NOS and both overall and lymphoma-specific survival even after adjusting for common variables. These results warrant validation in future prospective studies.

Indexed as

Lymphoma, T-Cell, PeripheralFemaleHumansLymph NodesMaleMiddle AgedPrognosisProspective StudiesNOSprimay lymphoma sitePTCLsurvival outcomes

Identifiers

PMID38073461
PMCPMC10757122
OpenAlexW4389566552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.